Meeting
2023 ASCO Annual Meeting
Iadademstat in combination with gilteritinib for patients with mutated FLT3 relapsed/refractory acute myeloid leukemia.
Authors
Amir Tahmasb Fathi
Massachusetts General Hospital, Harvard Medical School, Boston, MA
Amir Tahmasb Fathi , Mabel Arévalo , Sonia Gutierrez , Antonieta Molero , Natalia Sacilotto , Ana E. Limon , Douglas V. Faller
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Track
Hematologic Malignancies
Sub Track
Acute Leukemia
Clinical Trial Registration Number
NCT05546580
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS7075)
DOI
10.1200/JCO.2023.41.16_suppl.TPS7075
Abstract #
TPS7075
Poster Bd #
204a
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Comparison of dose modification strategies to address expected hematologic toxicities in treatment-naïve higher-risk (HR) MDS patients treated with venetoclax + azacitidine.
First Author: Jacqueline Suen Garcia
Poster
2023 ASCO Annual Meeting
Updated efficacy and safety data from the AGILE study in patients with newly diagnosed acute myeloid leukemia treated with ivosidenib + azacitidine compared to placebo + azacitidine.
First Author: Stéphane De Botton
Poster
2023 ASCO Annual Meeting
Analysis of short-term efficacy and safety of mitoxantrone hydrochloride liposome regimen therapy in adult acute myeloid leukemia.
First Author: Jun Ma
Poster
2022 ASCO Annual Meeting
Efficacy and safety of venetoclax in combination with azacitidine or decitabine in an outpatient setting in patients with untreated acute myeloid leukemia.
First Author: Sudhir Manda